Vyriad says it will showcase its modular G-Link CAR-T delivery platform at ASGCT, presenting new options for retargeting lentiviral vectors for in vivo delivery. The protein adapter, developed with Menachem Rubenstein, PhD, of the Weizmann Institute, is designed as a “plug-and-play” layer to cap and retarget existing vectors without extensive vector re-engineering. Vyriad positions G-Link as a way to shorten development timelines for next-generation in vivo CAR T and other cell therapies, and to simplify ex vivo manufacturing by improving T cell transduction efficiency. The company also said the platform supports clinical translation plans over time. Vyriad’s VV169 in vivo CAR-T program is expected to progress into clinical development later this year, while G-Link itself targets longer-term translation. The presentation highlights how delivery tooling has become a key competitive factor for cell therapy developers seeking scalable approaches.